Document is current
Any future updates will be listed below
-
Authors
Sedlaczek, Oliver Lukas http://orcid.org/0000-0002-8709-5481
Kleesiek, Jens
Gallagher, Ferdia A.
Murray, Jacob
Prinz, Sebastian
Perez-Lopez, Raquel
Sala, Evia
Caramella, Caroline
Diffetock, Sebastian
Lassau, Nathalie
Priest, Andrew N.
Suzuki, Chikako
Vargas, Roberto
Giandini, Tommaso
Vaiani, Marta
Messina, Antonella
Blomqvist, Lennart K.
Beets-Tan, Regina G. H.
Oberrauch, Petra
Schlemmer, Heinz-Peter
Bach, Michael
,
-
Funding
Funding for this research was provided by:
Cancer Core Europe
- License Information
-
More Information
Article History
Received: 25 March 2022
Revised: 25 March 2022
Accepted: 12 May 2022
First Online: 9 June 2022
Declarations
:
: The scientific guarantor of this publication is Oliver Sedlaczek.
: The authors of this manuscript declare relationships with the following companies:Evis Sala: Co-founder, Lucida Medical; Consultant, Amazon; Speakers Bureau, Siemens & GSK.Andrew N Priest is financially supported by the Addenbrooke’s Charitable Trust and the National Institute for Health Research (Cambridge Biomedical Research Centre at the Cambridge University Hospitals NHS Foundation Trust). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care.
: No complex statistical methods were necessary for this paper.
: Written informed consent was not required for this study because volunteers were mainly the (co-)authors.
: Institutional Review Board approval was not required because volunteers were mainly the (co-)authors. Volunteers were enrolled under local IRB approvals for sequence testing and optimization.
: • prospective• experimental• multicenter study
